3 September 2020 

The European Medicines Agency (EMA) is reviewing an application of Dexamethasone Taw, submitted by Taw Pharma, as a potential treatment for hospitalised adults with Covid-19. EMA said that its human medicines committee, CHMP, will assess the benefits and risks of the drug candidate within the shortest possible timeframe.

An analysis of seven international clinical trials showed that treatment with corticosteroid drugs cuts the risk of death by 20% in critically ill Covid-19 patients. Based on these findings, the World Health Organization (WHO) has updated its treatment guidance, recommending the use of steroids for severe and critical Covid-19.

Russia has granted approval for a Phase III clinical trial of China-based CanSino Biologics‘ Covid-19 vaccine candidate, developed in alliance with the Chinese military’s research arm. The trial of the Ad5-nCoV vaccine candidate has been launched in Moscow. CanSino will work with Petrovax Pharm to conduct the trials in Russia.

Parnell Pharmaceuticals has developed a topical nasal spray, called Nomovid, as prophylaxis against Covid-19. The spray is based upon a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi. Studies showed the substance to be more than 99.9% effective in-vitro against the SARS-CoV-2 virus. Parnell is seeking emergency use authorisation for the medication in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.